Portal de Periódicos da CAPES

Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus

2021; Elsevier BV; Volume: 161; Issue: 3 Linguagem: Inglês

10.1053/j.gastro.2021.04.080

1528-0012

Christopher Ma, Alain Schoepfer, Ekaterina Safroneeva, Christopher Ma, Alain Schoepfer, Evan S. Dellon, Albert J. Bredenoord, Mirna Chehade, Margaret H. Collins, Brian G. Feagan, Glenn T. Furuta, Sandeep Gupta, Ikuo Hirano, Vipul Jairath, David A. Katzka, Rish K. Pai, Marc E. Rothenberg, Alex Straumann, Seema S. Aceves, Jeffrey A. Alexander, Nicoleta C. Arva, Dan Atkins, Luc Biedermann, Carine Blanchard, Antonella Cianferoni, Constanza Ciriza de los Ríos, Frederic Clayton, Carla M. Davis, Nicola de Bortoli, Jorge Amil Dias, Gary W. Falk, Robert M. Genta, Gisoo Ghaffari, Nirmala Gonsalves, Thomas Greuter, Russell J. Hopp, Karen S. Hsu Blatman, Elizabeth T. Jensen, Doug Johnston, Amir F. Kagalwalla, Helén Larsson, John Leung, Hubert Louis, Joanne C. Masterson, Calies Menard‐Katcher, Paul Menard‐Katcher, Fouad J. Moawad, Amanda B. Muir, Vincent A. Mukkada, Roberto Penagini, Robert D. Pesek, Kathryn A. Peterson, Philip E. Putnam, Alberto Ravelli, Edoardo Savarino, Christoph Schlag, Philipp Schreiner, Dagmar Simon, Thomas C. Smyrk, Jonathan M. Spergel, Tiffany Taft, Ingrid Terreehorst, Tim Vanuytsel, Carina Venter, Mário C. Vieira, Michael Vieth, Berber Vlieg‐Boerstra, Ulrike von Arnim, Marjorie M. Walker, Joshua B. Wechsler, Philip Woodland, John T. Woosley, Guang‐Yu Yang, Noam Zevit, Ekaterina Safroneeva,

IL-33, ST2, and ILC Pathways

There has been tremendous interest in developing eosinophilic esophagitis (EoE)–specific pharmacotherapies,1 and more than 50 active or enrolling interventional studies are currently registered on ClinicalTrials.gov. Recent positive results from phase 3 trials of dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha, budesonide orodispersible tablets as both induction and maintenance therapy, and budesonide oral suspension, have inspired even greater enthusiasm for drug development in this field.